Fig. 4.

RNA expression of IAP-ERV and B2 SINE retrotransposons is increased by CORT treatment in C6 cells via the glucocorticoid receptor.

Fold change compared to control at both 1hr and 2hr is shown for 100 μM CORT treated cells (mean ± SEM). Expression experiments were independently replicated three times to verify the effect, the data shown and analyzed is from the first experiment. After 1hr incubation with 100 μM CORT, IAP-ERV expression is significantly increased by an average of 3.11 fold relative to control (Fig. 4A., Student's t-test, n = 3 per group, p < 0.01). After 2hr incubation with 100 μM CORT, IAP-ERV expression is significantly increased by an average of 32.44 fold relative to control (Fig. 4A., Student's t-test, n = 3 per group, p < 0.001). Likewise, after 1hr incubation with 100 μM CORT, B2 SINE expression is significantly increased by an average of 7.53 fold relative to control (Fig. 4B., Student's t-test, n = 3 per group, p < 0.05). After 2hr incubation with 100 μM CORT, B2 SINE expression is significantly increased by an average of 27.08 fold relative to control (Fig. 4B., Student's t-test, n = 3 per group, p < 0.001). After 1hr incubation with 100 μM CORT, IAP-ERV expression is significantly increased relative to control (Fig. 4C, Tukey's post-hoc, n = 3 per group, p < 0.0001). Co-treatment with GR-specific antagonist, RU486, blocks CORT induction (Fig. 4C, Tukey's post-hoc, n = 3 per group, p < 0.0001). Interestingly, RU486 alone appears to reduce IAP expression compared to control (Fig. 4C, Tukey's post-hoc, n = 3 per group, p < 0.01). Likewise, after 1hr incubation with 100 μM CORT, B2 SINE expression is significantly increased relative to control (Fig. 4D, Tukey's post-hoc, n = 3 per group, p < 0.05). Co-treatment with GR-specific antagonist, RU486, blocks CORT induction (Fig. 4D, Tukey's post-hoc, n = 3 per group, p < 0.01).